GP40081 + NovoMix 30
Phase 3UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 2
Conditions
Diabetes Mellitus, Type 2, Diabetes Mellitus
Trial Timeline
Jan 20, 2020 → Dec 25, 2020
NCT ID
NCT04226105About GP40081 + NovoMix 30
GP40081 + NovoMix 30 is a phase 3 stage product being developed by GEROPHARM for Diabetes Mellitus, Type 2. The current trial status is unknown. This product is registered under clinical trial identifier NCT04226105. Target conditions include Diabetes Mellitus, Type 2, Diabetes Mellitus.
What happened to similar drugs?
20 of 20 similar drugs in Diabetes Mellitus, Type 2 were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
4
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04226105 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Diabetes Mellitus, Type 2